Hutchmed (China)
HCM
Enerpac Tool
EPAC
Ermenegildo Zegna NV
ZGN
Lantheus
LNTH
eBay
EBAY
US Stock MarketDetailed Quotes
SGMO Sangamo Therapeutics
- 0.956
- -0.044-4.39%
Close Feb 25 16:00 ET
- 0.960
- +0.004+0.39%
Post 19:43 ET
199.49MMarket Cap-1.35P/E (TTM)
1.010High0.910Low5.05MVolume1.010Open1.000Pre Close4.85MTurnover2.49%Turnover RatioLossP/E (Static)208.65MShares3.17952wk High5.09P/B193.82MFloat Cap0.30452wk Low--Dividend TTM202.72MShs Float51.375Historical High--Div YieldTTM10.00%Amplitude0.291Historical Low0.960Avg Price1Lot Size
Sangamo Therapeutics Stock Forum
Sign in to post a comment
$Sangamo Therapeutics (SGMO.US)$ this quarter result is good or bad? No volume at all
3
Potential Spikes this Month Frfr, SGMO,APGE,UTHR,ZNTL,VTYX,CCCC,OCUL,GHRS,GLUE,RAPP,CING......
2
$Sangamo Therapeutics (SGMO.US)$
Revolutionary Fabry Disease Treatment Eliminates Need for Enzyme Therapy in All Patients
Revolutionary Fabry Disease Treatment Eliminates Need for Enzyme Therapy in All Patients
$Sangamo Therapeutics (SGMO.US)$ Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
3 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR)...
3 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR)...
$Sangamo Therapeutics (SGMO.US)$
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Thursday, 6th February at 8:05 am
Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR) slope obs...
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Thursday, 6th February at 8:05 am
Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date
Positive mean estimated glomerular filtration rate (eGFR) slope obs...
1
$Sangamo Therapeutics (SGMO.US)$ sell more, i want good discount
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway | 4D Molecular Therapeutics
2
1
$Sangamo Therapeutics (SGMO.US)$ lets go~~~~up
No comment yet
102477371 : When is the results ?
102414580 OP 102477371 : I do search on Google which projected on 18 February
72445797 : no result for this quarter at all. very weird. Not a good sign.